Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E17.80 EPS (ttm)5.65 Insider Own0.40% Shs Outstand1.51B Perf Week-1.45%
Market Cap151.74B Forward P/E10.14 EPS next Y9.92 Insider Trans-0.51% Shs Float1.50B Perf Month-6.16%
Income9.41B PEG0.74 EPS next Q2.25 Inst Own91.90% Short Float3.47% Perf Quarter-6.39%
Sales20.70B P/S7.33 EPS this Y10.40% Inst Trans-1.25% Short Ratio3.36 Perf Half Y22.42%
Book/sh8.96 P/B11.23 EPS next Y24.67% ROA34.00% Target Price122.63 Perf Year40.42%
Cash/sh4.19 P/C24.02 EPS next 5Y24.06% ROE69.10% 52W Range63.50 - 116.83 Perf YTD33.93%
Dividend- P/FCF15.08 EPS past 5Y11.90% ROI18.70% 52W High-13.91% Beta0.73
Dividend %- Quick Ratio1.80 Sales past 5Y16.00% Gross Margin82.70% 52W Low58.39% ATR3.41
Employees6100 Current Ratio2.10 Sales Q/Q117.10% Oper. Margin58.60% RSI (14)39.25 Volatility2.55% 3.10%
OptionableYes Debt/Eq0.69 EPS Q/Q255.30% Profit Margin45.40% Rel Volume1.08 Prev Close100.59
ShortableYes LT Debt/Eq0.58 EarningsOct 28 AMC Payout0.00% Avg Volume15.44M Price100.58
Recom1.70 SMA20-6.35% SMA50-4.78% SMA20012.25% Volume16,738,265 Change-0.01%
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Jul-28-14Reiterated Maxim Group Buy $112 → $127
Jul-24-14Reiterated RBC Capital Mkts Outperform $96 → $102
Apr-28-14Reiterated Maxim Group Buy $101 → $112
Feb-21-14Reiterated Barclays Overweight $90 → $95
Feb-10-14Reiterated Argus Buy $84 → $90
Feb-05-14Reiterated RBC Capital Mkts Outperform $90 → $96
Feb-05-14Reiterated Needham Buy $85 → $95
Feb-05-14Reiterated Maxim Group Buy $98 → $101
Feb-04-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
Jan-28-14Reiterated Deutsche Bank Buy $95 → $132
Jan-06-14Reiterated UBS Buy $80 → $102
Jan-02-14Reiterated Maxim Group Buy $89 → $98
Dec-20-13Reiterated RBC Capital Mkts Outperform $80 → $90
Nov-01-13Reiterated Argus Buy $70 → $84
Nov-21-14 01:11PM  Good Week for Gilead's Hepatitis-C Treatments, UBS Says at Barrons.com
12:28PM  AbbVie, Celgene, Sanofi Drugs Get EU Endorsements at Investor's Business Daily
Nov-20-14 03:27PM  Gilead to Buy Knight Therapeutics' Priority Review Voucher Zacks
01:48PM  Ooh La La: France Negotiates a Steep Discount for Sovaldi From Gilead at The Wall Street Journal
08:20AM  France pegs Gilead hepatitis C drug at "lowest price in Europe" Reuters
Nov-19-14 04:57PM  Gilead Gains on Harvoni's EU Approval for HCV Treatment Zacks
03:41PM  How Much? Gilead Pays $125M For an FDA Priority Review Voucher at The Wall Street Journal
01:12PM  Gilead Sciences: The Worst Case Scenario? at Barrons.com
10:23AM  Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU Zacks
Nov-18-14 02:39PM  The Buzziest Biotech Stocks on Social Media Yahoo Finance Blogs
02:38PM  Stock Movers: Why 4 Big Drug Stocks Are Rising Today at Investor's Business Daily
11:46AM  Gilead Sciences: Harvoni Gets European Marketing OK at Barrons.com
10:48AM  Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni at TheStreet
10:07AM  European Commission Grants Marketing Authorization for Gileads HarvoniĀ® (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 Business Wire
Nov-17-14 05:28PM  Halliburton Paying a Premium for Baker Hughes at The Wall Street Journal
04:27PM  GILEAD SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Ob EDGAR Online
03:58PM  Incyte Building Blockbuster Drug One Disease At A Time at Investor's Business Daily
10:03AM  Gilead: What About Its Pipeline? at Barrons.com
Nov-15-14 09:57AM  Julian Robertson's Tiger Management 13F Reveals Huge Alibaba Stake Benzinga
Nov-14-14 06:22PM  Biotech Stocks Hit: Stock Market To See New Leaders? at Investor's Business Daily
05:00PM  Biotech correction coming? 16 trades, 55 seconds CNBC
04:21PM  All in all, another solid week for U.S. equities... Yahoo Finance Blogs
01:04PM  GILEAD SCIENCES INC Financials EDGAR Online Financials
08:48AM  Can Gilead Double From Here? at Forbes
Nov-13-14 08:20PM  Are Health Care Funds Taking PEDs? at Investor's Business Daily
06:58PM  Which Health Care ETF Should You Buy? at Investor's Business Daily
05:45PM  Stock Pops & Drops: KING, BABA, SNDK & GILD CNBC
03:48PM  Can Gilead Recover from 3Q? at Barrons.com
01:37PM  Gilead Sciences In Correction Mode Benzinga
09:15AM  4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic at 24/7 Wall St.
08:31AM  Is A Boston University Professor's Plan For Lower Drug Costs Viable? at Forbes
07:36AM  The Zacks Analyst Blog Highlights: Dendreon, Amgen, Regeneron, AbbVie and Gilead Zacks
Nov-12-14 06:02PM  Your first trade for Thursday at CNBC
05:59PM  Gilead Prices $4 Billion of Senior Unsecured Notes Business Wire
04:00PM  Gilead Reports Promising Data on its HCV Drug Harvoni Zacks
01:35PM  Gilead Sees Large Insider Stock Sale Into Debt Offering at 24/7 Wall St.
12:59PM  FMHR Final Trade: Dunkin, Twitter & more CNBC
07:48AM  Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy Zacks
07:44AM  #PreMarket Primer: Wednesday, November 12: Banks Fined More Than $3 Billion For Role In Forex Manipulation Benzinga
Nov-11-14 11:26AM  Gilead hepatitis C drug highly effective in cirrhosis patients Reuters
09:00AM  AbbVie Hepatitis C Drug Cures 97% in Transplant Patients Study at Bloomberg
08:31AM  Stock Market News for November 11, 2014 Zacks
08:00AM  Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C Business Wire
08:00AM  Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment Business Wire
Nov-10-14 07:00PM  Cramer: This stock has years of upside CNBC
06:52PM  Merck: 4-week hepatitis C treatment too short at CNBC
06:00PM  Cramer: Default to big themes CNBC
05:50PM  Big pharma's liver battle CNBC
04:46PM  Shire CEO Looks Ahead To Independent Future at Investor's Business Daily
04:21PM  S&P, Dow again rise to record closes amid earnings at CNBC
02:17PM  Achillion rises on new hepatitis C drug study AP
02:04PM  Stock Movers: Why These 5 Top Stocks Are Rising Today at Investor's Business Daily
12:39PM  Merck, Dendreon miss out on health-care rally at MarketWatch
11:40AM  [video]Merck's Hepatitis C Study Falls Short, Its Loss Is Gilead's Gain at TheStreet
11:10AM  Hep C Patients Are Biggest Winners in Competitive Race for New Cures Yahoo Finance Blogs
09:29AM  RBC Sees Weak Merck Data As Positive For Gilead Benzinga
08:59AM  Premarket: Stock Futures Mixed; Gilead Climbs On Merck News at Investor's Business Daily
Nov-09-14 07:03PM  Merck 4-week hep C regimen with Gilead's Sovaldi comes up short Reuters
06:53PM  Mercks Four-Week Hepatitis C Regimen Fails to Top Gilead at Bloomberg
06:23PM  Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal at TheStreet
Nov-07-14 07:08PM  10-Q for Gilead Sciences, Inc. Company Spotlight
05:50PM  Gilead (GILD) Submits HIV Combination Drug for FDA Review Zacks
04:36PM  Stock Movers: Why These 4 Medical Stocks Dived Today at Investor's Business Daily
11:58AM  Stocks to watch ahead of liver disease conference at CNBC
10:32AM  Humana Misses On ObamaCare Spending, Hep C Costs at Investor's Business Daily
10:05AM  Humana, Hurt By Sovaldi, Sees ACA and Medicare Boon In 2015 at Forbes
09:57AM  A Few Good Ten in the Nasdaq 100 Yahoo Finance Blogs
09:40AM  Gilead Sciences: Another Big Jump in Hep-C Prescriptions at Barrons.com
Nov-06-14 08:30AM  Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV Business Wire
Nov-05-14 04:52PM  J&J Wins U.S. Approval for Hepatitis C Combo With Gilead at Bloomberg
04:29PM  GILEAD SCIENCES INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-04-14 10:39AM  Regeneron: That Was Disappointing at Barrons.com
05:00AM  'Fast Money' Recap: Lower Oil Prices a Warning Sign for Stocks at TheStreet
Nov-03-14 05:45PM  Stock Pops & Drops: NVDA, GILD, SUNE & GPRO CNBC
05:31PM  Q3 Profit, Sales Growth Approaching Recent Best Investor's Business Daily
10:10AM  Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed Zacks
09:55AM  Cramer's Stop Trading: Stratasys & BioMarin CNBC
07:55AM  #PreMarket Primer: Monday, November 3: Commercial Space Travel Questioned After Failed Flights Benzinga
05:56AM  Surging Earnings Estimates Signal Good News for Gilead (GILD) Zacks
Oct-31-14 05:36PM  Fundamentals, Technicals Still Intact At Gilead Sciences at Investor's Business Daily
05:26PM  Today's Market Thorns, Roses, All Time Highs, and ETF All Time Highs Yahoo Finance Blogs
02:25PM  AbbVie Beats Q3 Earnings Estimates, Raises Guidance at Investor's Business Daily
11:48AM  Gilead Sciences: Harvoni Still Selling Like Hotcakes at Barrons.com
06:00AM  Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX at TheStreet
Oct-30-14 08:11PM  Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong at TheStreet
05:54PM  [video]Netflix and Gilead Will See More Gains, Says Thornburg Value Manager at TheStreet
05:31PM  Veeva Systems Flies High On Cloud For Life Sciences at Investor's Business Daily
05:21PM  Market Thorns, Roses, All Time Highs, and ETF All Time Highs... Yahoo Finance Blogs
05:21PM  Facebook, Twitter, Amazon And Gilead: Musketeers Wielding Blunted Swords? at Forbes
03:42PM  [video]Phibro, Gilead Will See More Gains Says Thornburg Value Manager at TheStreet
08:55AM  Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings at 24/7 Wall St.
Oct-29-14 02:56PM  [$$] Gilead: Buy the Dip at Barrons.com
12:37PM  4 Stocks, 4 trades: GT, PNRA, HSY & GILD CNBC
11:26AM  Limited downside seen in Gilead optionMONSTER
10:50AM  Gilead Sciences Suffers 'Sloppy' Quarter on 'Unimportant' Sovaldi Sales at Barrons.com
10:37AM  Gilead Sciences (GILD) Stock Declines After Weak Third-Quarter Results at TheStreet
10:31AM  Stocks Stage Mixed Start; Facebook Drags Down Nasdaq at Investor's Business Daily
09:30AM  Gilead Sciences (GILD) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
09:22AM  Cramer's Mad Dash: US Steel leaner & meaner CNBC
08:00AM  Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially Zacks
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLIGAN JOHN FPresident and COONov 07Option Exercise8.01146,8951,175,8941,120,943Nov 12 12:48 PM
MILLIGAN JOHN FPresident and COONov 07Sale107.37146,89515,772,736974,048Nov 12 12:48 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000055,832Nov 07 01:20 PM
Carter Paul RutherfordEVP Commercial OpsNov 04Option Exercise0.004,800037,044Nov 05 05:37 PM
Whitley Richard JamesDirectorNov 03Option Exercise26.995,000134,95020,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Option Exercise8.01140,6251,125,7034,570,012Nov 05 02:05 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Option Exercise40.563,000121,68035,244Nov 05 05:37 PM
Washington Robin LEVP, CFONov 03Option Exercise25.1433,192834,58683,024Nov 05 08:06 PM
Whitley Richard JamesDirectorNov 03Sale112.025,000560,09015,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Sale110.40140,62515,525,1024,429,387Nov 05 02:05 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Sale112.463,000337,38032,244Nov 05 05:37 PM
Washington Robin LEVP, CFONov 03Sale110.2633,1923,659,83749,832Nov 05 08:06 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Option Exercise40.562,00081,12034,244Oct 28 01:35 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Sale110.002,000220,00732,244Oct 28 01:35 PM
Cogan John FrancisDirectorOct 21Option Exercise14.3415,000215,06357,405Oct 23 01:54 PM
Cogan John FrancisDirectorOct 21Sale104.0815,0001,561,14942,405Oct 23 01:54 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise8.01146,8951,175,8941,120,943Oct 09 02:10 PM
MILLIGAN JOHN FPresident and COOOct 07Sale104.60146,89515,365,818974,048Oct 09 02:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise23.7631,000736,405153,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.01140,6251,125,7034,570,012Oct 03 02:57 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale105.9833,0003,497,259120,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Sale105.91140,62514,893,8454,429,387Oct 03 02:57 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Option Exercise40.562,00081,12034,244Sep 30 01:19 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Sale107.472,000214,94532,244Sep 30 01:19 PM
Cogan John FrancisDirectorSep 22Option Exercise14.345,00071,68847,405Sep 24 01:20 PM
Cogan John FrancisDirectorSep 22Sale106.605,000532,98742,405Sep 24 01:20 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise8.01146,8951,175,8941,120,943Sep 10 04:06 PM
MILLIGAN JOHN FPresident and COOSep 08Sale105.99146,89515,569,664974,048Sep 10 04:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Option Exercise23.7631,000736,405155,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Option Exercise8.01140,6251,125,7034,570,012Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Option Exercise26.995,000134,95020,641Sep 04 04:31 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Sale108.5833,0003,583,230122,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Sale108.64140,62515,277,9144,429,387Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Sale108.105,000540,50015,641Sep 04 04:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Option Exercise19.0910,000190,85042,244Aug 28 02:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Sale106.1610,0001,061,61832,244Aug 28 02:35 PM
Cogan John FrancisDirectorAug 21Option Exercise14.345,00071,68847,405Aug 25 12:21 PM
Cogan John FrancisDirectorAug 21Sale101.095,000505,44042,405Aug 25 12:21 PM
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Option Exercise26.9916,728451,48948,713Aug 12 04:25 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Sale91.5816,7281,531,88131,985Aug 12 04:25 PM
MARTIN JOHN CChairman and CEOAug 01Option Exercise8.01140,6251,125,7034,570,012Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Option Exercise26.995,000134,95020,641Aug 05 05:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise0.002,500033,205Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Option Exercise22.3030,600682,49080,432Aug 05 01:35 PM
MARTIN JOHN CChairman and CEOAug 01Sale91.53140,62512,871,8134,429,387Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Sale91.005,000455,00015,641Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Sale91.4830,6002,799,34849,832Aug 05 01:35 PM
MOORE NICHOLAS GDirectorJul 28Option Exercise26.6245,0001,197,67545,000Jul 30 12:17 PM
MOORE NICHOLAS GDirectorJul 28Sale90.5645,0004,075,4030Jul 30 12:17 PM
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM
Cogan John FrancisDirectorJul 21Sale89.675,000448,34342,405Jul 23 01:31 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
Whitley Richard JamesDirectorJul 01Sale83.655,000418,25015,641Jul 02 04:24 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM
Washington Robin LEVP, CFOJun 30Sale83.9810,400873,40346,774Jul 02 01:44 PM
Cogan John FrancisDirectorJun 23Option Exercise14.345,00071,68847,405Jun 25 01:51 PM
Cogan John FrancisDirectorJun 23Sale81.825,000409,12342,405Jun 25 01:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Option Exercise16.4090,0001,475,550209,302Jun 18 04:33 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Sale80.9090,0007,280,784119,302Jun 18 04:33 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Option Exercise26.9916,728451,48947,433Jun 11 12:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Sale79.4316,7281,328,64530,705Jun 11 12:59 PM
Washington Robin LEVP, CFOJun 04Sale82.526,426530,27457,174Jun 05 05:46 PM
Whitley Richard JamesDirectorJun 02Option Exercise26.995,000134,95020,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Option Exercise23.6031,000731,600161,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Option Exercise8.01140,6251,125,7034,570,012Jun 04 02:48 PM
MARTIN JOHN CChairman and CEOJun 02Sale81.32140,62511,435,8364,429,387Jun 04 02:48 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Sale81.3533,0002,684,514128,694Jun 04 05:21 PM
Whitley Richard JamesDirectorJun 02Sale80.955,000404,75015,641Jun 04 05:18 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Option Exercise16.4090,0001,475,550209,302May 16 02:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Sale80.6590,0007,258,752119,302May 16 02:52 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000021,290May 13 02:27 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Option Exercise23.3340,000933,132170,694May 12 03:38 PM
MILLIGAN JOHN FPresident and COOMay 08Option Exercise8.01100,000800,5001,038,048May 09 06:58 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Sale80.0040,0003,200,000130,694May 12 03:38 PM
Washington Robin LEVP, CFOMay 06Option Exercise24.913,00074,71552,832May 08 07:13 PM
Washington Robin LEVP, CFOMay 06Sale79.913,000239,73049,832May 08 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise21.5811,000237,325143,694May 05 05:23 PM
Whitley Richard JamesDirectorMay 01Option Exercise26.995,000134,95017,778May 05 05:36 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise8.01140,6251,125,7034,570,012May 05 05:52 PM
MARTIN JOHN CChairman and CEOMay 01Sale79.02140,62511,112,0344,429,387May 05 05:52 PM
Whitley Richard JamesDirectorMay 01Sale78.635,000393,15012,778May 05 05:36 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale79.0813,0001,028,024130,694May 05 05:23 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Option Exercise16.4090,0001,475,550209,302Apr 16 12:34 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Sale67.0390,0006,032,482119,302Apr 16 12:34 PM
Cogan John FrancisDirectorApr 08Option Exercise14.345,00071,68844,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise24.4316,728408,68945,290Apr 10 03:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale70.5316,7281,179,78228,562Apr 10 03:52 PM
Cogan John FrancisDirectorApr 08Sale70.555,000352,75539,542Apr 10 02:52 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise8.01140,6251,125,7034,570,012Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise21.5811,000237,325145,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Option Exercise26.995,000134,95018,116Apr 03 04:00 PM
Whitley Richard JamesDirectorApr 01Sale73.095,000365,45013,116Apr 03 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale73.2013,000951,640132,694Apr 03 03:20 PM